dc.contributor
Institut Català de la Salut
dc.contributor
[Osterlund E, Hammarström K, Mathot L, Sjöblom T] Department of Immunology, Genetics and Pathology, Uppsala University, Uppsala, Sweden. [Nunes L] Department of Immunology, Genetics and Pathology, Uppsala University, Uppsala, Sweden. Department of Molecular Oncology, Institute for Cancer Research, Oslo University Hospital, Oslo, Norway. [Mezheyeuski A] Department of Immunology, Genetics and Pathology, Uppsala University, Uppsala, Sweden. Molecular Oncology Group, Vall d’Hebron Institute of Oncology (VHIO), Barcelona, Spain
dc.contributor
Vall d'Hebron Barcelona Hospital Campus
dc.contributor.author
Osterlund, Emerik
dc.contributor.author
Sjöblom, Tobias
dc.contributor.author
Hammarström, Klara
dc.contributor.author
Nunes, Luis
dc.contributor.author
Mathot, Lucy
dc.contributor.author
Mezheyeuski, Artur
dc.date.accessioned
2025-10-25T05:37:00Z
dc.date.available
2025-10-25T05:37:00Z
dc.date.issued
2025-08-12T07:13:35Z
dc.date.issued
2025-08-12T07:13:35Z
dc.date.issued
2025-05-28
dc.identifier
Osterlund E, Hammarström K, Nunes L, Mathot L, Mezheyeuski A, Sjöblom T, et al. Primary tumour location, molecular alterations, treatments, and outcome in a population-based metastatic colorectal cancer cohort. BJC Reports. 2025 May 28;3:38.
dc.identifier
http://hdl.handle.net/11351/13524
dc.identifier
10.1038/s44276-025-00156-z
dc.identifier.uri
http://hdl.handle.net/11351/13524
dc.description.abstract
Primary tumour; Molecular alterations; Metastatic colorectal cancer
dc.description.abstract
Tumor primari; Alteracions moleculars; Càncer colorectal metastàtic
dc.description.abstract
Tumor primario; Alteraciones moleculares; Cáncer colorrectal metastásico
dc.description.abstract
Background: Metastatic colorectal cancer (mCRC) patients in trials are selected. The aim was to study mCRC features population-based.
Methods: All 765 mCRC patients in the Uppsala region, Sweden, 2010-2020 were identified and analysed for RAS (n = 356/708) and BRAF-V600E (n = 123/708) mutations (mt) and deficient mismatch repair (dMMR, n = 58/643).
Results: Right colon primary tumours were associated with BRAF-V600Emt and dMMR and had worse median overall survival (mOS) than left colon or rectal mCRC. RAS&BRAF wildtype (wt) and proficient MMR were seen in 22%, 45%, and 31% of right colon, left colon, and rectum, respectively. Patients with right colon primaries received best supportive care only more often (34% vs 25% vs 24%) and metastasectomy less often (21% vs 31% vs 33%) than left colon and rectal primaries. In molecularly homogeneous subgroups (RAS&BRAFwt/RASmt/BRAF-V600Emt/dMMR) no difference in mOS were seen between right and left colon primaries, whereas rectal primaries had better mOS (26/15/8/9 vs 24/21/8/8 vs 32/23/6/NA months, respectively). This was also the case in homogenous treatment groups. Primary tumour location turned non-significant in multivariable OS analyses.
Conclusions: The high variation of BRAF-V600Emt, RASmt, dMMR, and treatment allocation population-based per primary tumour location explain the poor outcome in right-sided cancers.
dc.description.abstract
This work was funded by grants from the Swedish Cancer Society (22 2054 Pj 01H), Lions Cancerforskningsfond Mellansverige, and an unrestricted start-up grant from Amgen. The funders had no role in the design of the study, nor in the analyses of data or the writing of this report. Open access funding provided by Uppsala University.
dc.format
application/pdf
dc.publisher
Springer Nature
dc.relation
BJC Reports;3
dc.relation
https://doi.org/10.1038/s44276-025-00156-z
dc.rights
Attribution 4.0 International
dc.rights
http://creativecommons.org/licenses/by/4.0/
dc.rights
info:eu-repo/semantics/openAccess
dc.subject
Anomalies cromosòmiques
dc.subject
Recte - Càncer - Tractament
dc.subject
Còlon - Càncer - Tractament
dc.subject
DISEASES::Neoplasms::Neoplasms by Site::Digestive System Neoplasms::Gastrointestinal Neoplasms::Intestinal Neoplasms::Colorectal Neoplasms
dc.subject
Other subheadings::Other subheadings::/therapy
dc.subject
DISEASES::Neoplasms::Neoplastic Processes::Neoplasm Metastasis
dc.subject
PHENOMENA AND PROCESSES::Genetic Phenomena::Genetic Variation::Mutation
dc.subject
ENFERMEDADES::neoplasias::neoplasias por localización::neoplasias del sistema digestivo::neoplasias gastrointestinales::neoplasias intestinales::neoplasias colorrectales
dc.subject
Otros calificadores::Otros calificadores::/terapia
dc.subject
ENFERMEDADES::neoplasias::procesos neoplásicos::metástasis neoplásica
dc.subject
FENÓMENOS Y PROCESOS::fenómenos genéticos::variación genética::mutación
dc.title
Primary tumour location, molecular alterations, treatments, and outcome in a population-based metastatic colorectal cancer cohort
dc.type
info:eu-repo/semantics/article
dc.type
info:eu-repo/semantics/publishedVersion
